LivingGLP1
Study S001478

Effects of Exenatide on Obesity and Appetite in Overweight Patients With Prader-Willi Syndrome

ClinicalTrials.gov record

Registration

Registration
NCT01444898
Study type
INTERVENTIONAL
Masking
NONE
Status
COMPLETED
Enrollment
10
Start
2012-03
Primary completion
2013-05
Lead sponsor
Children's Hospital Los Angeles
Conditions
Prader-Willi Syndrome
Interventions
DRUG:Exenatide
Results posted
TRUE
Individual participant data sharing
UNDECIDED

Registered primary outcomes

  • Change in Weight [6 months]
  • % Change in Body Mass Index (BMI) [6 months]
  • Change in BMI Z-Score [6 months]
  • Change in HbA1c (%) [6 months]
  • Change in Insulin Levels [6 months]
  • Change in Leptin [6 months]
  • Change in Acy Ghr [6 months]
  • Change in Pancreatic Peptide (PP) [6 months]
  • Appetite Scores [6 months]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0017214Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.
Salehi P, Pediatric obesity
2017Randomized trialPMID 27071367DOIregistry reference RESULT:27071367
R0023335Treating diabetes mellitus in Prader-Willi syndrome with Exenatide.
Seetho IW, Diabetes research and clinical practice
2011Case reportPMID 21227526DOIregistry reference BACKGROUND:21227526
R0026955Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes.
Rosenstock J, Diabetes care
2010Randomized trialPMID 20332357DOIregistry reference BACKGROUND:20332357
R0026979Exendin-4 potently decreases ghrelin levels in fasting rats.
Pérez-Tilve D, Diabetes
2007PreclinicalPMID 17192476DOIregistry reference BACKGROUND:17192476